Industry News
Amrad to change its name
Melbourne's Amrad Corporation (ASX:AML) will be seeking approval from shareholders to change its name. [ + ]
Medical Therapies narrows focus, issues new prospectus
Unable to secure sufficient funds with its first attempt at an IPO, Sydney-based Medical Therapies has issued a replacement prospectus which CEO Llewellyn Casbolt believes has "uncluttered and demystified the company and its technologies". [ + ]
Eqitx, Mimotopes sign partnering deal
Eqitx (ASX:EQX) and PharmAust (ASX:PAA) subsidiary Mimotopes have signed a partnership deal to jointly develop new targets for therapeutic or diagnostic approaches. [ + ]
Cryptome to chase opps in vascular field
Melbourne biopharma Cryptome Pharmaceuticals (ASX:CRP) has signed a collaboration agreement with the University of Virginia for the further discovery of compounds to treat 'vascular leak' -- a major component of inflammatory disorders and tissue damage associated with stroke, heart attacks and MS. [ + ]
EvoGenix licenses leukaemia antibody
Antibody developer EvoGenix (ASX:EGX) has signed a licensing deal with Dinona for one of the South Korean biotech's anti-leukaemia antibodies. [ + ]
Agenix aims to raise $9.85m
Brisbane-based Agenix (ASX:AGX, NASDAQ:OTC:AGXLY) has lodged a prospectus for an underwritten non-renounceable rights issue to raise $9.85 million before costs. [ + ]
CogState turns focus from biotech
Melbourne-based CogState (ASX:CGS) has distanced itself from the biotech sector, in a move that CEO Peter Bick described as "bowing to popular pressure that biotechs are highly risky and expensive businesses". [ + ]
Development in coherent x-ray science
La Trobe University is one of a number of Australian and overseas universities and other organisations sharing a $9 million ARC grant over five years to develop a Centre of Excellence in Coherent X-ray Science.
[ + ]Russian approval granted for Norwood EyeCare products
Norwood Devices, a division of medical technologies group Norwood Abbey (ASX:NAL) has received approval from the Russian Ministry of Health to import and sell the Norwood EyeCare Epi-LASIK system. [ + ]
SSH aims to raise $4.3m for Bio-Layer
Sydney-based SSH Medical (ASX:SSH) has started accepting applications for subscriptions to raise approximately $4.3 million to provide working capital for material science company Bio-Layer, which SSH is acquiring. [ + ]
Avastra files for new BioWeld patent
Sydney-based Avastra (ASX:AVS) has filed a provisional patent on the use of its BioWeld technology in conjunction with surgical glues and adhesives. [ + ]
Starpharma investee Dimerix raises $1m
Dimerix Bioscience has closed a series A capital raising worth almost AUD$1 million, and has revealed plans to accelerate the development of its new compounds created by applying its technologies to novel G-protein coupled receptor (GPCR) cluster targets. [ + ]
Biota confirms Relenza orders from US, France, Hong Kong
Melbourne-based Biota Holdings (ASX:BTA) has confirmed that three more countries have placed orders for Relenza, the anti-flu drug developed by Biota and commercialised by Britain's GlaxoSmithKline (GSK). [ + ]
Out, damned spot: wheat disease faces genetic nemesis
Wheat stem rust, an inexorable pathogen of Australia's wheat belt since 1925, is destined to be run over by the genetic equivalent of a four-decker bus. [ + ]
First enrolment for Pharmaxis Aridol COPD study
Drug developer Pharmaxis (ASX:PXS) has enrolled its first patient for the phase II clinical trial to assess the ability of Aridol to predict the usefulness of inhaled corticosteroids as a treatment of chronic obstructive pulmonary disease (COPD). [ + ]
